Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Cti Biopharm Corp (CTIC)

Cti Biopharm Corp (CTIC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 158,575
  • Shares Outstanding, K 96,692
  • Annual Sales, $ 0 K
  • Annual Income, $ -52,450 K
  • 60-Month Beta 0.69
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.59
Trade CTIC with:

Options Overview Details

View History
  • Implied Volatility 157.44%
  • Historical Volatility 133.37%
  • IV Percentile 90%
  • IV Rank 49.49%
  • IV High 266.68% on 11/17/21
  • IV Low 50.42% on 07/21/21
  • Put/Call Vol Ratio 0.36
  • Today's Volume 734
  • Volume Avg (30-Day) 2,394
  • Put/Call OI Ratio 0.24
  • Today's Open Interest 37,999
  • Open Int (30-Day) 21,233

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate -0.07
  • Number of Estimates 2
  • High Estimate 0.08
  • Low Estimate -0.22
  • Prior Year -0.20
  • Growth Rate Est. (year over year) +65.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5900 +1.57%
on 12/02/21
2.9100 -44.50%
on 11/05/21
-1.0550 (-39.51%)
since 11/02/21
3-Month
1.5900 +1.57%
on 12/02/21
3.2200 -49.84%
on 09/10/21
-1.4650 (-47.56%)
since 09/02/21
52-Week
1.5900 +1.57%
on 12/02/21
4.1300 -60.90%
on 03/22/21
-1.6750 (-50.91%)
since 12/02/20

Most Recent Stories

More News
Biotech Stock Roundup: VRTX, AMGN's Pipeline Updates, BPMC's Acquisition & More

Pipeline updates from Vertex (VRTX) and Amgen (AMGN) and other acquisition and regulatory updates have been the biotech sector's few key highlights during the past week.

CTIC : 1.5200 (-7.32%)
AMGN : 201.96 (+0.58%)
VRTX : 205.30 (+0.15%)
BPMC : 98.01 (+2.06%)
DCPH : 7.94 (-0.75%)
Implied Volatility Surging for CTI BioPharma (CTIC) Stock Options

Investors need to pay close attention to CTI BioPharma (CTIC) stock based on the movements in the options market lately.

CTIC : 1.5200 (-7.32%)
Lineage Cell: Q3 Earnings Snapshot

CARLSBAD, Calif. (AP) _ Lineage Cell Therapeutics, Inc. (LCTX) on Wednesday reported a loss of $7.8 million in its third quarter.

CTIC : 1.5200 (-7.32%)
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors...

CTIC : 1.5200 (-7.32%)
CTI BioPharma (CTIC) Dips on Top-Line Data from COVID-19 Study

CTI BioPharma (CTIC) posts top-line data from the PRE-VENT study evaluating pacritinib/standard of care as a treatment of severe COVID-19 infection.

CTIC : 1.5200 (-7.32%)
INFI : 1.9800 (+1.05%)
GLMD : 2.40 (-0.83%)
ATXI : 1.2500 (-6.02%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strongest short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

CTI BioPharma Corp. is a biopharmaceutical company. It is focused on the acquisition, development and commercialization of therapies covering a spectrum of blood-related cancers. The company is heavily focused on marketing its approved therapy Pixuvri in Europe, and on continuing the development of its...

See More

Key Turning Points

3rd Resistance Point 2.2467
2nd Resistance Point 2.1133
1st Resistance Point 1.8767
Last Price 1.5200
1st Support Level 1.5067
2nd Support Level 1.3733
3rd Support Level 1.1367

See More

52-Week High 4.1300
Fibonacci 61.8% 3.1597
Fibonacci 50% 2.8600
Fibonacci 38.2% 2.5603
Last Price 1.5200
52-Week Low 1.5900

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar